^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

NI-2901

i
Other names: NI-2901, NI 2901, NI2901
Company:
Light Chain Biosci
Drug class:
PD-L1 inhibitor, CD47 inhibitor
Related drugs:
over1year
NI-2901, an affinity-optimized CD47xPD-L1 bispecific antibody for dual immune checkpoint blockade (AACR 2023)
PD-L1-independent CD47 antitumor activity was assessed in vivo in a PD-L1-negative xenograft model and compared to the anti-CD47 magrolimab analog...As a result, the bsAb is able to enhance the phagocytosis of PD-L1-negative and -positive tumor cell lines induced by mAbs targeting tumor-associated antigens (e.g. rituximab, trastuzumab and anti-CD19) and demonstrates in vivo activity in the Raji B-cell lymphoma xenograft model. Given its high affinity for PD-L1, NI-2901 triggers an effective blockade of the PD-1/PD-L1 interaction, inducing T-cell activation in vitro to a degree similar to anti-PD-L1 benchmark antibodies atezolizumab and avelumab...Also, NI-2901 demonstrated significant antitumor activity in vivo and is therefore expected to show improved clinical efficacy over PD-1/PD-L1 blockade alone. The bsAb was well-tolerated in NHP without inducing RBC or platelet depletion.
Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Checkpoint block
|
CD47 (CD47 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
|
PD-L1 expression • PD-L1 negative • CD47 expression
|
Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Rituxan (rituximab) • Bavencio (avelumab) • magrolimab (ONO-7913) • NI-2901